Versant Vantage I, L.P.
SEC CIK 1765253 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | 10% | 2,531 | — | — | 1 | 2024-04-09 | 2024-04-09 |
Most active insiders at CTNM, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Lorrain Daniel S. | CSO | — | $1.13M |
| 2 | Stengone Carmine N. | CEO, Pres, Dir | — | $401.4K |
| 3 | Watkins Tim | CMO, Head of Development | — | $322.6K |
Versant Vantage I, L.P. made no open-market trades at CTNM in the last 12 months.
Transactions 1
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2024-04-11 | 2024-04-09 | CTNM | Contineum Therapeutics, Inc. | Versant Vantage I, L.P. | 10% | C - Cnv Deriv | — | +542.6K | 2,531 | New | — |
Purchase Sale Sale after option exercise All abbreviations